Synergistic immunomodulatory effects of interferon-β1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing- remitting multiple sclerosis

Annals of Neurology

Volumn 44, Issue 1, 1998, Pages 27-34

  Weber, Frank ^a   Polak, Thomas ^a   Günther, Astrid ^a   Kubuschok, Boris ^a   Janovskaja, Julia ^a   Bitsch, Andreas ^a   Poser, Sigrid ^a   Rieckmann, Peter ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; LYMPHOTOXIN; MYELIN BASIC PROTEIN; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CHILL; CLINICAL ARTICLE; DRUG ACTIVITY; DRUG EFFECT; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; MULTIPLE SCLEROSIS; MYALGIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; BASE SEQUENCE; CELLS, CULTURED; CHI-SQUARE DISTRIBUTION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKINS; LYMPHOTOXIN-ALPHA; MULTIPLE SCLEROSIS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0031902917     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440109     Document Type: Article

References (35)

1. Wekerle H, Linington C, Lassmann H, Meyermann R. Cellular immune reactivity within the CNS. Trends Neurosci 1986;9: 271-277
2. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23: 339-346
3. Olsson T. Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma. J Neuroimmunol 1992;40:211-218
4. Beck J, Rondot P, Catinot L, et al. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323
5. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88
6. The IFNb Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
7. Paty DW, Li DKB, the UBC MS/MRI Study Group, The IFNb Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
8. Jacobs LD, Cookfair DL, Rudick RA, et al. Intrapmuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294
9. Byskosh PV, Reder AT. Interferon-β1b effects on cytokine mRNA in peripheral mononuclcar cells in multiple sclerosis. Multiple Sclerosis 1996;1:262-269
10. Rudge P, Miller D, Crimlisk H, Thorpe J. Does Interferon beta cause initial exacerbation of multiple sclerosis? Lancet 1995; 345:580 (Letter)
11. Rieckmann P, Weber F, Günther A, et al. Pentoxifylline, a phosphodiesterase inhibitor induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996;64:193-200
12. Rieckmann P, Weber F, Günther A, Poser S. The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-β1b treatment in patients with multiple sclerosis. Neurology 1996;47:604 (Letter)
13. Eylar EH, Kniskern PJ, Jackson JJ. Myelin basic proteins. Methods Enzymol 1979;32B:323-341
14. Pette M, Fujita K, Kitze B, et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990;40:1770-1776
15. Weber F, Meinl E, Drexler K, et al. Transformation of human T cell clones by herpesvirus saimiri: intact antigen recognition by autonomously growing myelin basic protein-specific T cells. Proc Natl Acad Sci USA 1993;90:11049-11053
16. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990;8:579-622
17. Linington C, Berger T, Perry L, et al. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 1993;23:1364-1372
18. Mor F, Cohen IR. T cells in the lesion of experimental autoimmune encephalomyelitis: Enrichment for reactivities to myelin basic protein and to heat shock proteins. J Clin Invest 1992; 90:2447-2455
19. Kojima K, Berger T, Lassmann H, et al. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia. J Exp Med 1994;180:817-829
20. Powell MB, Mitchell D, Lederman J, et al. Lymphotoxin and tumor necrosis facror-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol 1990;2:539-544
21. Racke MK, Bonomo A, Scott DE, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994;180:1961-1966
22. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994; 24:1434-1440
23. Cannela B, Gao Y-L, Brosnan CF, Raine CS. IL-10 enhances experimental allergic encephalomyelitis (EAE). J Neuroimmunol 1994;24:155 (Abstract)
24. Skias DD, Reder AT. IL-10 inhibits EAE. Neurology 1995;45: A349 (Abstract)
25. Salmaggi A, Dufour A, Eoli M, et al. Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression? J Neurol 1996;243:13-17
26. Voskuhl RR, Martin R, Bergman C, et al. T helper 1 (TH1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 1993;15:137-143
27. Hemmer B, Vergelli M, Calabresi P, et al. Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99). J Neurosci Res 1996;45:852-862
28. Hermans G, Stinissen P, Hauben L, et al. Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals. Ann Neurol 1997;42:18-27
29. Milo R, Panitch H. Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J Neuroimmunol 1995;61: 185-193
30. Pette M, Pette DF, Muraro PA, et al. Interferon-beta interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. Neurology 1997;49:385-392
31. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor penroxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 1993;23:1745-1751
32. Rep MH, Hintzen RQ, Polman CH, van Lier RA. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol 1996;67:111-118
33. Platzer C, Meisel C, Vogt K, et al. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol 1995;7:517-523
34. Pfeffer LM, Constantinescu SN, Reder AT, eds. Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997; 1-39
35. Stricter RM, Remick DG, Ward PA, et al. Cellular and and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988;155: 1230-1236